• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

管理筛查间隔的延长:避免医疗保健工作量的大起大落。

Managing an extension of screening intervals: Avoiding boom and bust in health care workloads.

机构信息

Cancer Prevention Group, School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK.

出版信息

Int J Cancer. 2023 May 15;152(10):2061-2068. doi: 10.1002/ijc.34441. Epub 2023 Feb 1.

DOI:10.1002/ijc.34441
PMID:36691808
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10952902/
Abstract

Extending screening intervals in ongoing cancer screening programmes can lead to challenging year-on-year variations in the number of screening tests. We explored how such variation could be diminished with a managed transition to the extended interval. We defined three extension scenarios: immediate extension for the entire target population; stepped transition by birth cohort; and gradual transition by reducing the number of available screening appointments. These were compared to a situation in which the interval remains unchanged in a demographic model covering a 15-year period. The model was populated with observed parameters from England, a real-world setting recommending cervical screening with 3-year intervals at age 25-49 and 5-year intervals at age 50-64. Informed by typical changes currently considered by several European programmes including the programme in England, we explored the effect on screening test numbers of an extension of the 3-year interval to 5 years for women younger than 50. All three extension scenarios resulted in similar cumulative numbers of screening tests, which were about 30% lower compared to a situation in which the interval would remain unchanged. However, the year-on-year variation in the number of screening tests varied between the scenarios. This variation was around 4-fold for the immediate scenario. In the stepped scenario, the yearly numbers could differ by around 20%, whereas in the gradual scenario they were virtually constant. A managed interval extension, transitioning different groups of the target population at different times, can substantially reduce the yearly variation in screening workload without increasing the total number of screening tests in the long term.

摘要

在正在进行的癌症筛查计划中延长筛查间隔可能会导致每年筛查测试数量的显著变化。我们探讨了如何通过管理过渡到延长的间隔来减少这种变化。我们定义了三种扩展方案:对整个目标人群立即扩展;按出生队列逐步过渡;以及通过减少可用筛查预约数量逐步过渡。这些方案与在涵盖 15 年的人口模型中保持不变的间隔情况进行了比较。该模型使用来自英格兰的观察参数进行了填充,这是一个现实世界的背景,建议 25-49 岁女性每 3 年进行一次宫颈癌筛查,50-64 岁女性每 5 年进行一次。根据目前包括英格兰计划在内的几个欧洲计划正在考虑的典型变化,我们探讨了将 3 年间隔延长至 5 年对 50 岁以下女性筛查测试数量的影响。所有三种扩展方案都导致了相似的累积筛查测试数量,与间隔不变的情况相比,大约降低了 30%。然而,筛查测试数量的逐年变化在不同的方案之间存在差异。对于立即扩展的情况,这种变化大约是 4 倍。在逐步扩展的方案中,每年的数量可能相差约 20%,而在逐步扩展的方案中,数量几乎是恒定的。通过管理间隔扩展,在不同时间过渡目标人群的不同群体,可以在不增加长期总筛查测试数量的情况下,大幅减少筛查工作量的年度变化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef6f/10952902/02850f5c629c/IJC-152-2061-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef6f/10952902/078974d3306e/IJC-152-2061-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef6f/10952902/dcb27a5e92dd/IJC-152-2061-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef6f/10952902/02850f5c629c/IJC-152-2061-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef6f/10952902/078974d3306e/IJC-152-2061-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef6f/10952902/dcb27a5e92dd/IJC-152-2061-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef6f/10952902/02850f5c629c/IJC-152-2061-g004.jpg

相似文献

1
Managing an extension of screening intervals: Avoiding boom and bust in health care workloads.管理筛查间隔的延长:避免医疗保健工作量的大起大落。
Int J Cancer. 2023 May 15;152(10):2061-2068. doi: 10.1002/ijc.34441. Epub 2023 Feb 1.
2
Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.高危型人乳头瘤病毒检测的宫颈癌筛查项目中,筛查间隔超过 5 年的安全性:荷兰基于人群的随机队列 14 年随访。
BMJ. 2016 Oct 4;355:i4924. doi: 10.1136/bmj.i4924.
3
The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen.每3年进行一次人乳头瘤病毒/细胞学联合宫颈筛查对人群的影响:降低宫颈癌风险并减少每次筛查中癌前病变的检出率。
Cancer. 2016 Dec 1;122(23):3682-3686. doi: 10.1002/cncr.30277. Epub 2016 Sep 22.
4
HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.HPV 检测与常规细胞学检查在宫颈癌筛查中的比较:ARTISTIC RCT 的长期随访。
Health Technol Assess. 2019 Jun;23(28):1-44. doi: 10.3310/hta23280.
5
A study of the effect of introducing a restrictive cervical screening policy on laboratory workload and cervical cancer detection rates.一项关于引入限制性宫颈癌筛查政策对实验室工作量和宫颈癌检出率影响的研究。
Cytopathology. 1990;1(1):13-7. doi: 10.1111/j.1365-2303.1990.tb00321.x.
6
The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.英格兰原发性人乳头瘤病毒子宫颈筛查的临床效果和成本效益:通过三轮筛查对 ARTISTIC 随机试验队列进行的扩展随访。
Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230.
7
[Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].[卫生技术评估报告:基于人乳头瘤病毒DNA的宫颈癌前病变初筛]
Epidemiol Prev. 2012 May-Aug;36(3-4 Suppl 1):e1-72.
8
High-grade cervical abnormalities and screening intervals in New South Wales, Australia.澳大利亚新南威尔士州的高级别宫颈异常与筛查间隔
J Med Screen. 2008;15(1):36-43. doi: 10.1258/jms.2008.007036.
9
Cervical cancer screening by cotesting method for Vietnamese women 25-55 years old: a cost-effectiveness analysis.越南25至55岁女性联合检测法宫颈癌筛查的成本效益分析。
BMJ Open. 2025 Jan 22;15(1):e082145. doi: 10.1136/bmjopen-2023-082145.
10
Extension of cervical screening intervals with primary human papillomavirus testing: observational study of English screening pilot data.以人乳头瘤病毒检测为基础的宫颈癌筛查间隔时间的延长:英国筛查试点数据的观察性研究。
BMJ. 2022 May 31;377:e068776. doi: 10.1136/bmj-2021-068776.

引用本文的文献

1
Predictable changes in the accuracy of human papillomavirus tests after vaccination: review with implications for performance monitoring in cervical screening.疫苗接种后 HPV 检测准确性的可预测变化:对宫颈筛查中性能监测的影响的综述。
Br J Cancer. 2024 May;130(11):1733-1743. doi: 10.1038/s41416-024-02681-z. Epub 2024 Apr 13.

本文引用的文献

1
Extension of cervical screening intervals with primary human papillomavirus testing: observational study of English screening pilot data.以人乳头瘤病毒检测为基础的宫颈癌筛查间隔时间的延长:英国筛查试点数据的观察性研究。
BMJ. 2022 May 31;377:e068776. doi: 10.1136/bmj-2021-068776.
2
The impact of catch-up bivalent human papillomavirus vaccination on cervical screening outcomes: an observational study from the English HPV primary screening pilot.二价型人乳头瘤病毒疫苗补种对宫颈癌筛查结果的影响:来自英国 HPV 初级筛查试验的观察性研究。
Br J Cancer. 2022 Jul;127(2):278-287. doi: 10.1038/s41416-022-01791-w. Epub 2022 Mar 26.
3
Age-specific outcomes from the first round of HPV screening in unvaccinated women: Observational study from the English cervical screening pilot.
未接种 HPV 疫苗女性首轮 HPV 筛查的年龄特异性结局:英国宫颈筛查试点的观察性研究。
BJOG. 2022 Jul;129(8):1278-1288. doi: 10.1111/1471-0528.17058. Epub 2022 Jan 18.
4
The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.英国英格兰国家 HPV 疫苗接种计划对宫颈癌和 3 级宫颈上皮内瘤变发病率的影响:基于登记的观察性研究。
Lancet. 2021 Dec 4;398(10316):2084-2092. doi: 10.1016/S0140-6736(21)02178-4. Epub 2021 Nov 3.
5
Impact of disruptions and recovery for established cervical screening programs across a range of high-income country program designs, using COVID-19 as an example: A modelled analysis.以 COVID-19 为例,对一系列高收入国家不同项目设计的既定宫颈癌筛查项目中断和恢复的影响:模型分析。
Prev Med. 2021 Oct;151:106623. doi: 10.1016/j.ypmed.2021.106623. Epub 2021 May 23.
6
Cervical screening during the COVID-19 pandemic: optimising recovery strategies.COVID-19 大流行期间的宫颈癌筛查:优化恢复策略。
Lancet Public Health. 2021 Jul;6(7):e522-e527. doi: 10.1016/S2468-2667(21)00078-5. Epub 2021 Apr 30.
7
Impact of the COVID-19 pandemic on human papillomavirus-based testing services to support cervical cancer screening.2019年冠状病毒病大流行对支持宫颈癌筛查的人乳头瘤病毒检测服务的影响。
Acta Dermatovenerol Alp Pannonica Adriat. 2021 Mar;30(1):21-26.
8
Introducing human papillomavirus (HPV) primary testing in the age of HPV vaccination: projected impact on colposcopy services in Wales.在人乳头瘤病毒(HPV)疫苗接种时代引入HPV初筛:对威尔士阴道镜检查服务的预计影响
BJOG. 2021 Jun;128(7):1226-1235. doi: 10.1111/1471-0528.16610. Epub 2020 Dec 15.
9
HPV Vaccination and the Risk of Invasive Cervical Cancer.HPV 疫苗接种与浸润性宫颈癌风险。
N Engl J Med. 2020 Oct 1;383(14):1340-1348. doi: 10.1056/NEJMoa1917338.
10
Impact of changes to cervical screening guidelines on age and interval at which women are tested: Population-based study.宫颈筛查指南改变对女性接受检查的年龄和间隔的影响:基于人群的研究。
J Med Screen. 2021 Sep;28(3):325-332. doi: 10.1177/0969141320953446. Epub 2020 Aug 30.